Skip to main content
Erschienen in: Reactions Weekly 1/2021

01.03.2021 | Case report

Ibrutinib

Neutropenia following compassionate use of ibrutinib: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Pardy N, et al. Expanding the indications for ibrutinib: Complete remission obtained by induction with ibrutinib followed by consolidative aHSCT in refractory primary CNS lymphoma ]. Current Oncology 27: E664-E665 abstr. 2, No. 6, Jan 2020. Available from: URL: http://doi.org/10.3747/co.27.7151 [abstract] Pardy N, et al. Expanding the indications for ibrutinib: Complete remission obtained by induction with ibrutinib followed by consolidative aHSCT in refractory primary CNS lymphoma ]. Current Oncology 27: E664-E665 abstr. 2, No. 6, Jan 2020. Available from: URL: http://​doi.​org/​10.​3747/​co.​27.​7151 [abstract]
Metadaten
Titel
Ibrutinib
Neutropenia following compassionate use of ibrutinib: case report
Publikationsdatum
01.03.2021
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2021
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-021-93206-z

Weitere Artikel der Ausgabe 1/2021

Reactions Weekly 1/2021 Zur Ausgabe

Case report

Indometacin

Case report

Atorvastatin

Case report

Thalidomide

Case report

Adalimumab